Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers.
Target Price
The average target price of KAPA is 7.00 and suggests 300% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre